• News & Media
  • Contact
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Posters and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • KOMET-007 – AML
    • KOMET-008 – AML
    • Tipifarnib Clinical Trials
    • KURRENT-HN – HNSCC
    • KO-2806 Clinical Trials
    • FIT-001 – Solid Tumors
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • News & Media
  • Contact
  • Menu Menu

Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni, Kura Oncology

August 1, 2024/in 2024, Media Coverage, Perspectives, Year
Read more
https://kuraoncology.com/wp-content/uploads/Empowered_Patient_Podcast.jpg 450 800 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-08-01 15:00:432024-08-01 16:43:02Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni, Kura Oncology

Menin inhibitors seek to debut as newest targeted therapy for leukaemia

August 1, 2024/in 2024, Media Coverage, Perspectives, Year
Read more
https://kuraoncology.com/wp-content/uploads/Nature.jpg 450 800 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-08-01 13:00:102024-11-06 12:49:06Menin inhibitors seek to debut as newest targeted therapy for leukaemia

Moving Forward, Giving Back: The ROI of Social Impact

June 27, 2024/in 2024, Media Coverage, Perspectives, Year
Read more
https://kuraoncology.com/wp-content/uploads/MovingForwad_GivngBack.jpg 450 800 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-06-27 13:00:032024-06-28 10:28:21Moving Forward, Giving Back: The ROI of Social Impact

Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML

March 21, 2024/in 2024, Media Coverage, Perspectives, Year
Read more
https://kuraoncology.com/wp-content/uploads/OncLive.png 304 557 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-03-21 18:38:282024-03-21 19:49:24Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML

Kura Oncology Reports Preliminary Data From Menin Inhibitor, Chemo Combination Trial in AML

March 21, 2024/in 2024, Media Coverage, Perspectives, Year
Read more
https://kuraoncology.com/wp-content/uploads/Precision_Medicine_Online.png 304 557 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-03-21 18:20:582024-11-06 12:12:16Kura Oncology Reports Preliminary Data From Menin Inhibitor, Chemo Combination Trial in AML

Kura’s Leukemia Treatment Performs Best When Tacked Onto Existing Combo, New Data Show

March 21, 2024/in 2024, Media Coverage, Perspectives, Year
Read more
https://kuraoncology.com/wp-content/uploads/fierce_bio.png 304 557 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-03-21 11:43:012024-03-22 15:20:19Kura’s Leukemia Treatment Performs Best When Tacked Onto Existing Combo, New Data Show

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

February 15, 2024/in 2024, Media Coverage, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/SC2402_Scrip-Asks-24-Part-5_1888758571_1200.jpg 444 790 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-02-15 13:38:472024-02-15 13:39:44Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

PharmaVoice’s Crystal Ball: Perspectives on the financial future

January 9, 2024/in 2024, Media Coverage, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/PV-Outlook.png 852 1524 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2024-01-09 10:44:432024-01-09 11:08:08PharmaVoice’s Crystal Ball: Perspectives on the financial future

Kathy Ford, R.N., B.S.N., Kura COO, on Ordinarily Extraordinary – Conversations with Women in STEM podcast

December 20, 2023/in 2023, Media Coverage, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/Kathy-Ford-podcast-image.jpg 792 2142 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2023-12-20 17:25:442023-12-21 15:55:25Kathy Ford, R.N., B.S.N., Kura COO, on Ordinarily Extraordinary – Conversations with Women in STEM podcast

Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place

December 1, 2023/in 2023, Media Coverage, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/Manu_Supply_Chain.jpg 375 710 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2023-12-01 15:14:492023-12-07 11:34:23Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place
Page 1 of 212
  • About Us
  • Our Commitment
  • The Story Behind Our Name
  • Leadership
  • Board of Directors
  • Our Approach
  • Precision Medicines
  • Overcoming Resistance
  • Novel Biomarkers
  • Pipeline
  • Ziftomenib
  • Tipifarnib
  • KO-2806
  • Posters and Presentations
  • Scientific Manuscripts
  • Access to Investigational Drugs Outside a Clinical Study
  • Clinical Trials
  • Overview of Clinical Trials
  • Ziftomenib Clinical Trials
  • KOMET-001 – AML
  • KOMET-007 – AML
  • KOMET-008 – AML
  • Tipifarnib Clinical Trials
  • KURRENT-HN – HNSCC
  • KO-2806 Clinical Trials
  • FIT-001 – Solid Tumors
  • Patients & Caregivers
  • Acute Leukemias
  • Head & Neck Cancer
  • Investors
  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financial Information
  • Analyst Coverage
  • FAQs
  • Contact
  • Careers
  • Values
  • Life at Kura
  • Benefits
  • Open Positions
  • News & Media
  • Press Releases
  • News & Perspectives
  • Expert Perspectives
  • Media Resources
  • Contact

Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego, CA 92130
(858) 500-8800

Kura Oncology, Inc.
2 Seaport Lane, Suite 8A
Boston, MA 02210
(617) 588-3755

Kura Oncology, Inc.
5510 Morehouse Drive, Suite 110
San Diego, California 92121

© 2025 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy

Scroll to top Scroll to top Scroll to top